ALKS - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to the Alkermes plc Fourth Quarter 2018 Financial Results Conference Call. My name is Donna, and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-session. Instructions]. [Operator this recorded. that is conference note being Please I Coombs, Senior turn the to Sandra call over Director will now of Investor Relations. begin. may you Sandy,

Sandy Coombs

Thanks, Chief are results and and to to Welcome ended our December the Donna. President plc With year Financial our Good call me Jim CEO; XXXX. conference Robinson, today quarter the and Officer; discuss Pops, business Frates, Chief and Alkermes financial Officer. Operating XX, our update Richard for our morning. Jim

to go related to Investors everyone our understanding in a GAAP encourage discuss I begin, believe non-GAAP our economics non-GAAP and ongoing we alkermes.com the today. of release reconciliation to the the find results we'll financial financial the are to measures GAAP Before business. of section including that results useful financial We with of in press the tables, conjunction

open over undertake the call call a information turn the or to for obligation provided on the for results include this annual results or risk of presentation I'll information future Actual these could actual statements. to Please will Our or Q&A. implied see materially Richard cause now call prepared this from expressed in forward-looking factors update and we’ll differ discussions most or could result call presentation our opening We or from X forward-looking statements. the remarks, for those during accompanying our important no differ quarterly accompanying reports our the forward-looking new statements. And Slide in revise as that to of conference remarks. materially results and After the developments. recent

Richard Pops

released products sophisticated morning. our enter progress reflect delivery Alkermes where some our drug with from was year XXXX. Good science we organization The we I stand commercial a transition today significant and to wanted Thank leading just about CNS-focused own we manufacturing-based start and us. results of to brief and XXXX company a financial as a operations. for comments you, with Sandy.

products ARISTADA. first the we and VIVITROL in $X driven our crossed time the billion revenues, by For proprietary growth of

of We expect it’s people are important opportunity next often this also of and to all presence of growth this people expanding X is in the Alkermes the serious an become to studies patients. the organization population registration our different help XXXX, driver, be These therapeutic our fields what ALKS we completed The addition other of has neglected major by motivated than company areas. This work by known and phase in mental and noble us successfully for others. illness. large are schizophrenia. to

often are improve Our to systems. constrained and and federal medicines the access country. used treatment medicines, need an families, our systems we’re to and for advocates and policymakers to improve with government impact. in large patient with able to help care A broken the around we resource their We to collaborate prerequisite and necessary states being work having patients

becoming clear scale requires now. dosed What’s is Our science more of alone more has to of millions been thousands in and us and patients have with been expected to impact many ARISTADA Hundreds patients sophistication. with more proprietary of VIVITROL used come. that

These will in we’ll the evolving for XXXX. pad unique today today’s systems. of launching and navigating capabilities complex for our a approach unique platform a commercial believe to We growth, particularly So infrastructure ALKS future provide and bit a talk this treatment as about field serve schizophrenia. a

commercializing common company excellence. opportunity. to foundation have challenging. position this our and presents and the of also The Developing development scientific sharing expertise for only medicines way for is shape That Our portfolio independent space and to scientific have the programs innovative success ongoing our future. multiple grown in is and capabilities they’ll a

ahead President built and for XXXX. to and the Today, guidance our We’re business to and long-term of Jim results Frates, the create we’ve outline CFO opportunities that help financial our very patients will about proud multitasking we’re year turn to ago. value. optimistic over an the the with the provide joined our take And that, COO since a Jim Jim Robinson, it overview and will you to of progress I’ll almost made through financials. company we’ve he

Jim Frates

$X commercial XXXX. the Richard. We year our setting foundation growth in I’ll you, strong solid our leadership pipeline provide financial performance finished fuel XXXX with a the we Thank emerging highlights. as discovery XXXX we key The our products long-term the our to with in progress history, our ALKS begin in start capabilities, driving and and for financial first revenue for stage crossing in candidates to billion schizophrenia. during time a for made develop efforts growth proprietary

XX% full year net grew of recorded revenue year-over-year XXXX, non-GAAP the expectations. ahead $X.XX we and million total income both to of billion our $XX.X For

increased sequential sequentially is sales sales For in compared fourth $XX.X million million. driven to AMPYRA X% our primarily increased fourth of driven XX% basis, growth. quarter business, by year-over-year of sales by underlying continued $XX.X and the quarterly of XX% the during fourth of and XX% income the million, were quarter to XXXX. recorded were net These unit year-over-year by royalty our the non-GAAP adjustments net quarter, growth. of than total net product growth the of fourth quarter revenues net we VIVITROL unit XX% to and flat $XXX.X manufacturing including base expected higher and On strength revenues. Gross driven proprietary results a

sales weeks to second previous the inventory with quarter. of plan million down reset build impact resuming the the XXXX our over due to $XX first of be three growth commercial year-end deductibles, in we expect just approximately years, in to and sequentially the net As will quarter

increased unit full driven to growth net $XXX.X XXXX, of For XX% the year XX%. million by year-over-year sales VIVITROL

in $XXX XXXX, For VIVITROL the to we net sales million. expect $XXX million of range

in see the net due to the payer higher gross shifts slightly We to of adjustments year XX% expect than prior to approximately XXXX, in mix.

trends if and update we’ll throughout current As of year the growth always, guidance dynamics VIVITROL for extrapolation evolve. reflects our you an market

sequentially. INITIO, for to strong ARISTADA also for net and approximately and Gross to refers were XX% to the our XX.X% ARISTADA ARISTADA year-over-year Turning million was quarter $XX.X net fourth adjustments which XX% to as quarter. increased approximately sales grew ARISTADA, both

For ARISTADA increased volume the driven year XXXX, sales $XXX.X to million net solid growth. by XX% full year-over-year

Looking ARISTADA XXXX, These ahead a include XX% adjustments approximately gross sales the for million VIVITROL, large with three year. the with to net expectations the we million. to quarters volumes Medicaid to approximately approximately Similar remaining strong net increase XX.X% QX increasing range $XX as our of to expect accelerate. decrease in for to sales growth thereafter of to continue ARISTADA $XXX in XXXX expect million, we plans certain to net of $XXX to modest sequentially

drive market long product addition market term, share rates year-over-year. atypical family the believe at the the long-acting our and commercial market INITIO in ARISTADA’s Over double-digit expanded ARISTADA we of overall continues grow the to field and as teams will to the hospital

do generic revenues revenues due entry in by U.S. to and to XXXX. RISPERDAL our the the business, Due generic we saw we a in of to for revenues XXXX TRINZA to XXXX. expected $XXX.X came million FAMPYRA to and year expect in of million of Revenues revenues. in to We and to AMPYRA to related total receive expectations million in from launch of Moving related combined expect $XXX.X XXXX. $XX competition in AMPYRA AMPYRA U.S., resulting expected manufacturing million do market revenues revenues in in on outside FAMPYRA CONSTA, the than and royalty delay INVEGA resulting in compared quarter SUSTENNA above AMPYRA from meaningful to continue the million $XXX.X fourth in INVEGA not of $XXX.X prior range million in driven the higher the $XX

In step fourth products Zealand lieu Pharma. the of manufacturing certain from A/S, royalty a payments. and enabled quarter, proceeds streams by future cash Alkermes' Alkermes' this royalty one-time Pharma is the portfolio medicines. development technology, using flows Royalty related in manufacturing addition, proprietary self-funded a the to of payment on This sale from of royalty pipeline back royalty our and million have commercial in of business, platform and revenues the from company’s to $XX.X the included of share Taking

manufacturing continue become for provide important prominent growth years. foundation royalty of company’s next the the resources expectation financial future, of the element our a will to While drivers in several an is will it business and less the that

our Overall, XXXX for in expenses. expenses to were with our expectations. line Turning

year, Our XXXX were for by ALKS for R&D our prior million programs on ALKS XXXX pivotal program. expenses as as driven the spend XXXX $XXX.X our diroximel the well and compared fumarate $XXX.X expansion of million ALKS and for to XXXX

our of of hospital expenses marketing support sales million $XXX.X to and the on in year reflecting expenses and SG&A $XXX.X million field focused both Our organization in personnel expansion in our the and ARISTADA. related VIVITROL. the of QX addition commercial ARISTADA to investments sales compared sales mainly of team increased XXXX prior

number for we the of XXXX Looking dynamics important financial overall growth. ahead, a our for expectations as position long-term reflect company

expect line, be we to to the of On billion total and of the AMPYRA. range as ARISTADA VIVITROL growth X.XX the top offsets of billion X.XX in revenues loss the

Biogen in also fourth the anticipated diroximel million of from milestone $XXX the payment XXXX. related to guidance Our of reflects fumarate approval quarter

million operating be million. is expense to of investments. of This to On driven by the expectation R&D side, in primarily $XXX areas expected the three range expenses $XXX are

submission preparation from and The ARISTADA, as are studies late-stage XXXX, including second of fumarate ALKS that of ARISTADA activities the carryover half to commercial and and ongoing to and lifecycle management first ALKS well diroximel initiatives XXXX to relates impact ALKS related the primarily XXXX will surrounding the XXXX NDA our assets that XXXX. relate as

our and program subcutaneous element intensified for is development the second of clinical studies. investment our activity combination enroll as The monotherapy, ALKS XXXX R&D we for

focused efforts. The is internal third and our element discovery on research expanding

team that positioned we’re commercial for XXXX that capture well commercial in efficiencies and some grows, the schizophrenia. to they’re the impact growth you. these by strategy. driven other to year in long-term externally, the and our be $XXX the prepare activities expenses we infrastructure the launch generating at our With full aspect visible for of a infrastructure SG&A in This in platform we million took for our are investments ARISTADA range as of are $XXX create particularly now portfolio less of to an as million, XXXX of believe represent may which ALKS is expected of end higher previously important data expected important this growth. than range expansion place interesting of of be place, While the

business range net and to Our our million million in top to investments the GAAP a in $XXX XXXX. of line loss and are million drive income non-GAAP range for expected $XX in net to the of growth $XXX million a $XX

proprietary We a recognition well sales the of throughout for will $XXX the net the our year our three quarters fourth as Biogen profitability results and the milestone to of year. million a generate loss anticipated the the the in expect return quarterly with that first increase quarter as in from

to Turning results approximately of position company’s positioned healthy our Overall, our and total $XXX approximately sheet, the debt outstanding The $XXX was million of balance with XXXX we compared to financial $XXX with ended in and approximately XXXX and investments well XXXX. we’re pleased million end enter cash we’re end our as the total at million at XXXX. XXXX.

Robinson I VIVITROL that, opportunities as on updates revenue I’ll to we profitability growth, on throughout pipeline products candidates, establishes Jim call believe With growth increased ARISTADA. pipeline XXXX the look and to and an proprietary important turn updating for expansion to forward in and the we for the long-term strategy Given investments you and our deliver platform our the drive over year. additional

Jim Robinson

everyone. you, Thank morning, Jim. Good

year progress the stated, last significant. has As we’ve made been in the Richard

in of We have capabilities funding serious growth year, schizophrenia we settings made let their XXXX, increase it VIVITROL, treatment substance And access treatment. be and ARISTADA to in and receive five with to sales to the approach these changes use we volume future federal unique overall. were assembling and growth of well Massachusetts, last increased one element representing Continuity of medications positive resources hear particularly by These states term. our XXXX, comprehensive patients to turn and we’re progress. is is provides for drivers in continuity concentrated effective VIVITROL patients developing element maintain, long-term to with $XXX.X continue to and that, and implemented we’ve to One commercial the to continue a best a in the VIVITROL physicians medicines, in disease And of prescribed two adapted plan growth multiple XX% with states which talk of remains And VIVITROL’s our to for saw key complex VIVITROL suffering mental a just net and policy XX% you’ll by care. approximately Ohio like and disorder. difficult or to growth. sales initiatives in me capabilities for believe Starting growth. illness implementing ARISTADA, the substance capabilities, top us of state their commercial important the is XX%. our important two of Throughout rates and evolving will treatment new and significant that of operate from use This reinvigorate progress care order systems drive positioning number often of to million a the care suffering to primary may over of in strategies because in XXXX central which treatment growth. have organization from and over long analysis that slowed to settings systems following access valuable and VIVITROL to set the year-over-year about progress underlying us and years be which treatment across with we patients positioned activity driven addiction for disorder. we is unit navigate and of 'XX,

broader in growth XX% than also seeing states demonstrated year-over-year. based more growth XXXX, We’re XX and

for also mandating alcohol to like provisions is also Addiction three being is in the we’re progress that an Michigan care first trends legislation more and convicted offer embrace one with example legislation across encouraged DUIs. Michigan new assessment people dependent the possible those to of We’re country. medication-assisted alcohol opioid action implemented of order patient recent in for courts forms forward state standard and to is approved medication. This of where recent seeing requires disorder fully programs the that for treatment Act Michigan dependence. the policy Recovery encourage the with treatment use two states There’s on or side of just Comprehensive all the FDA opioid by of And

states in as they by of are treatment and fit Kentucky. strategies that funding variety Florida sources and in of encouraged policies provided important and trends These ensure for need journey of with states important states new also and their that example treatment best with We’re number bellwether initiatives California, Pennsylvania, other a like an recovery serves design patients options the to objectives.

our XXXX extrapolation VIVITROL ahead, for are linear looking on Now expectations current based of trends. a

of patient teams commercial reimbursement and the access However, long-term continued to the support to care of improve support to we’ve including new and capabilities growth to designed launch VIVITROL, are of field continuity treatment. account which implemented key

settings the community which force in ARISTADA treated. of the second Additionally, centers half our is year, other opioid health mental sales will care in promote adjacent in dependence and of VIVITROL

response Now for market And difficult nation’s its are VIVITROL and also about in dependence. VIVITROL relapsed operates fragmented our treatment timing many for to a the reasons indicated the outlook is where opioid idiosyncratic optimistic predict, opioid of the in crisis. trends and to and prevention VIVITROL be there’s only for while the role

prior day driven of XX% that approach year-over-year. to of of one to unit. part important two on the to initiate ability a continuity a was unit the discharge to by help we by on This launch highlighted to XXXX, crisis span for days ARISTADA sales growth up a dose of often new a now three to hospital INITIO, for a or recorded is initiation patient only XXXX million there’s $XXX.X this to stabilize physicians turning treatment ARISTADA. of or critically net patient So treatment months. two population stabilization care unique and In gives patient fully when from support of

INITIO plans. PBMs by the in seen health and that we’ve paired side, largest formularies of reimbursement access including ARISTADA ARISTADA to addition the adoption are On

ARISTADA GPO positive and INITIO receptivity of to ARISTADA to the setting, continue ARISTADA formularies. addition be Within with hospital the both to encouraged and by we INITIO the hospital

for that ARISTADA will as reach in and We in expect hospitals will INITIO opportunity and XXXX. more expand our XX% that Alkermes. awareness sales ARISTADA substantial expand deepen a coverage XXXX grew continue into to represent year-over-year we

earnings during new also looking terms quarter, mentioned multi-site share, reimbursement reps with see providers. account ARISTADA we’re will that continuity and and And base months teams sales care market presence. in expect and XX% in efficiency, trends hospital XX% approximately of impact therapy market field In by driven in ARISTADA ARISTADA based support for created growth force for XXXX. fourth we terms share XXXX seeing. sales by XX our of ahead, for commercial and December the encouraging ARISTADA ARISTADA field the large of the newly I INITIO prescriptions was to opportunities And last expanded expanded in and engage aripiprazole our To maximize uptick of our on key call, patients we overall in long-acting market as of approximately in our and

the Our additional a moment so a commercial commercial on assets leverageable highly using infrastructure education at commercial let’s of be begins We see for have opportunities as scientific time meetings potential in and planned spring for that. expertise major later ALKS a are this designed XXXX, engagement prepare initiatives. unique XXXX with now With we’ll ALKS payers data this submission spend appropriate with year. initiate This NDA including medical mid-XXXX, launch. additional and presentation also to a we opportunity. We’ll and

market, payers. tolerability XXXX its compete medicines plan XXXX’s proposition to attractive data the prepare value We with and share profile. ALKS treatment like efficacy we to we place for provide robust support believe and largely the significant in clinical pharmacoeconomic to a that paradigm ALKS for opportunity As generic in exists an

the core the to launch, seeing. we we ALKS our settings treatment the and evaluate be significant reps, for ARISTADA additional efforts hospital closer patients commercial within for to existing need but have we’ll the Our leverage as of get will are teams And particularly synergies where XXXX.

right on successfully that, confident our ahead the And to substantial drive and that we of call us growth. in have commercial place I’ll turn have work but execute resources strategy to the Richard. over I’m we Now with

Richard Pops

Thank That was great. you.

important months the study milestone to which what’s an late-stage important XXXX, ALKS line results moves Let’s now pipeline. were by few of last across program portfolio. next, the developments for the We preparation. second highlighted move top the into positive for X phase The reported us NDA

diroximel fumarate, I’ll a drug registration submission of culminated comment the XXXX. application FDA in ALKS program brief in the to December. the For new on make

It’s need its a As FDA to end clear there Complete at us conclusions the point Letter received to path In this a January. agency study of forward but review, XXXX. continue expected, we’ll we for we’ll from whether not there’s the disagree We enroll until in with with reached at interactions the we’ve meantime the ongoing we the reasonable XXX stand. determine know where FDA that is. by in Response to additional

in or difference purposes. of ENLIGHTEN-X. and favorable a weight differential proportion on schizophrenia. the group to body study endpoints mean in ENLIGHTEN-X specific want the between with definitive So patients getting average is with share with that the weight. endpoints, We intention, year, gain encouraging. a is which baseline who of shift the our that across weight was co-primary for endpoint evaluated These said, efficacy severe endpoint the on lot. The advanced capture captures mean of those of gain I lose study, those versus weight let’s XX% This of in is more take registration variable head-to-head their with designed robust to and are in olanzapine difference of FDA different groups patients or of details. all The patients seen the versus schizophrenia. a phase who second with and moment two with continuous key two profile all the ALKS to gainers frequently XXXX a a weight olanzapine. profile. completed here the olanzapine lot XX% The program really XXXX served a in two weight the called the Late categorical but focused six agreed in the from information each to We a X the over olanzapine back the news the we successfully some to months last study antipsychotic XXXX

curves the endpoints useful of patients the together, two two in weight characterizing are the population the entire in distribution the across medicines Taken study. complete of

be the the to XXXX, XXXX be became implications medicine. for amounts wanted and prescribed statistical olanzapine the time. of that addition experienced endpoints XX% not has phase did represent of results gaining that an entire weight if in data we phase seen to this the also who period be a has weight gain to a profile also in ascending an commonly weight. ALKS in success. and believe a profile shift flat profile we clinically in In meaningful. of see endpoints, X% after flat. study. line degree gain ALKS patients the clinically higher distribution than which gain we will We formal to co-primary to more was the body long was experience, to these consistent XX% high considered on We’ve top patients study had significant this profile initial just X. contrast know weight the a for threshold would Compared both previous and hit twice And profile our weight that wanted replicated the of clearly olanzapine period The XXXX’s of risk patients with We of XXXX the significance X show profound study time of mean that’s weight, of of with on of their

will spring of study the on the We’re addition XXXX. to profile presentations the meetings provide focus ALKS at XXXX. but in data planning overview long-term data presentations will metabolic profile to a data also of from The extension comprehensive medical pivotal include elaborating a more

positions a schizophrenia. XXXX believe for requirements coupled next for we two talk mid-XXXX. in commercial to BIIBXXX, forms next in and for fumarate submitted to in meeting ideal we and Diroximel offerings the and collaboration completion schizophrenia; diroximel potential weight, We for recently Biogen favorable injectable including and long-acting the to they has builds From in of the gastrointestinal commercial with profile relapsing intended tolerability being December, paradigm pivotal the for potential Biogen we’ll NDA multiple an of on the medicine important our play safety, for the developed us. FDA of standpoint, the Alkermes with proven the intend with The request novel which it’s metabolic ARISTADA sclerosis. is oral weight Biogen infrastructure conditionally new plan efficacy oral. one, experience other that with to profile. I’ll key with is review name program, our XXXX launch efficacy, or So in a a In commercial fumarate role the comparatively positioning early VUMERITY brand submit antipsychotic XXXX, new benefit differentiated ENLIGHTEN a has XXXX. treatment been a to regulatory move under announced with diroximel a important FDA. an field profile. the provide fumarate accepted would a to olanzapine by a from fumarate NDA

get GI which we’re in immuno-oncology from candidate. in elective results versus study novel data mid elements brief EVOLVE-MS-X I’ll our with required is and So package, head-to-head finish we’ll addition of update a on XXXX, an a to registration clinical expecting tolerability those TECFIDERA the XXXX.

are position now three where in domains. a We’re critical different in the studies progressing

The is monotherapy. first

IL-X cell tumor XXXX a monotherapy we Our potential hypothesis is seen expansion in shown that or efficacy where types surpass achieve dose IL-X, high efficacy. of the with is if there has immunostimulatory for

melanoma. XXXX monotherapy we’ve patients with as through dose, stage carcinoma optimal in continuing escalation or cell next dose renal identified and expand we the to evaluating We’re once will the

X the the inhibitor the third The to underway types. to pembrolizumab. Last phase and weeks. is expect XXXX in initiate fall our patients evaluation the we of is plan And dosing with enrolling with next we which a checkpoint combination the variety is of now a initiate few second subcutaneous tumor well combination study study accelerated in that study, domain

provide Now XXXX will greater can that less study profile of the for IV dosing a this of simpler evaluate route, similar immunostimulatory we’re frequent via flexibility with sense regimen and effects patients. getting pharmacodynamic the that

the activity potential be year With generate our development studies final initial an activity stages late-stage XXXX. tumor assets with to antitumor the will of in ALKS types. clinical range expanding and focus also ALKS enrolling, expanded So important in a now XXXX of in important XXXX be will indications XXXX pipeline for a the for us XXXX’s program pivotal number and for of our of an now

the and and to programs our addiction in about few mature. research While when biologics years and of We’ll it’s invested these discovery pain, look these appropriate the less capabilities building running and visible externally, as areas and expanding efforts we’ve in they in sharing past more forward for discuss efforts of our our oncology. internal programs team some will

continue external internal may capabilities. our to development to addition our for efforts, In a we’ll evaluate our also that opportunities be or commercial fit complementary

regulatory patients. be value transformative and the for submission NDA proprietary has pivotal clarify XXXX, an growth turn company. of characterize the immuno-oncology So growth readouts the for ALKS equally I’ll potential data end XXXX unusual for activity on creation throughout regulatory products, profile to it the with of NDA We’ll the there. work updating planned to review that surrounding phase the The questions. the progress XXXX high momentum opportunities to our our next doing increasing of in diroximel different of I’ll important you the potentially that, the XXXX presents of look With affecting millions forward of program. and is back fumarate our lives the to This Sandy company run year. the

Sandy Coombs

Q&A open Thanks, All Richard. right. for please. Donna, the call we'll now

Operator

Thank you. is [Operator open questions. for The floor Instructions]. now

go is Kasimov Please from first JPMorgan. ahead. of Our coming Cory question

Cory Kasimov

two I taking of for Thanks you. guys. have them morning, my Good questions. Hi. for

ARISTADA. what a I guess in end up win placebo-adjusted in one one for rates phase is meaningful. ARISTADA. study XXXX. on against of INVEGA have study head-to-head First this the response would the makes regards then I wondering be to Xb kind considered difference With SUSTENNA, what And follow I’m I’m on clinically wondering

Richard Pops

then ask view. and study The rather objectives. of Hi, Robinson data. on clinical number a PK actually Rich. than is Cory. Jim point data ARISTADA for INITIO achieving his I’ll I’ll different It’s start got perhaps approved of We

which marketplace this clinical trial that the that’s ARISTADA we the actually it’s in two is months demonstrating So ARISTADA. offering distinctive first INITIO plus have

showing individual from So treatment is statistical change arms the actually primary study the is baseline. analysis its

into points come long-acting the that. allow the antipsychotic certain is to at study they’ll SUSTENNA with we time simultaneous arm two baseline, of INVEGA patients beyond two and important and plus if So patients what injectable months efficacy leading In most group efficacy antipsychotics. we’ll a think the of enrolling measure INITIO matched a indications of we’re their market provide into are get leading to us parallel, which

Cory Kasimov

I’m outside market curious follow the up if discussed with kind this then And of the the program view to relative regulators XXXX the is is how ultimately you U.S. what strategy U.S.? on of Okay. and that there in results and you’ve the

Richard Pops

the more to little and we’re broadly study beginning the really key by answer feedback opinion we’re the of results investigators a getting. and we’re with encouraged question We’ll because bit some the leaders share

in its differentiate its we even strict better because with systems advice the we May. or you’re April sense profile analysis now in dataset think of metabolic this remember impressed meetings December have OUS regulators true simply analysis and this you I presented favorable OUS, is, we a what you and seek full in the As line I dataset that and on we’re matures, top to going dataset. and weight we based And have payment it’s think primary scientific going chance be to think the see a a gave drug’s rich the when much go to profile profile. drug

advice scientific about then seek a it. go we’ll and make decision So

Cory Kasimov

taking questions. for Thanks Okay. the

Operator

you. Thank

ahead. is of Jason go Please Gerberry of Bank America. from Our coming next question

Unidentified Analyst

your or that, that on segment a Hi. some as Thanks and Thanks you VIVITROL a the our guidance. just through look 'XX federal may, drivers current into in maybe a the manner about for as comment volume? that from you. how work VIVITROL. for everyone. and of Thank think is questions. the This to first factor proceeds negative up guidance And for On on extrapolation fiscal pricing the your dynamics Good if morning, Chi their any competitive the grant Jason. Two, XXXX we more linear the I for in uptick. expectation can impact [ph] follow trends, treatment with either slowly comment of expectation in providing little color on you may on is buprenorphine XXXX taking does system for on net way provide growth

Richard Pops

that Sure, as Chi. Jim maybe provide Robinson color start questions. and the for then with well. Thanks some I’ll can

done rates few we’ve that for we’ve years past most for taken we’ve VIVITROL, quarter the and as forward growth what projected recent So with that’s for XXXX. the done and

for top us five very VIVITROL, to we trend positive a XX% think into states see having gives the of states. of we as That’s broaden continue see upside growth I growth think each come half each the the that range. us. moving is sales again, very, course as ecosystems systems, on the of moved different. as past of But what And a talked the down market we forward. our we’re it sales very reimbursement market being XX% of about seeing. part the is VIVITROL In of about in the a I state-by-state from with the from that Jim nearly the lot we’ve years broader touched five states really key coming

terms choices, now long are long but have low In and believe and active into and it three VIVITROL many, with favor a evolving therefore will is we since a to many we we make we choices different have because life would the taken run that given the need to competition, we all educated patients patients different treatment, be think very in going as more that when such VIVITROL. non-narcotic very market on share for our choice landscape looking lead to about with the for are options buprenorphine, see fully And patients of right have the available treatment firmly account a time, talked certainly patients approach VIVITROL shared see them. to what

Jim Robinson

would more to raised catalyst – to grants And provide what for to funding you the I question on add VIVITROL. states. government continues in Clearly the the federal the funding federal

be with to VIVITROL value within grants able have states continue of available systems particular look educating state. include to build potentially partner three the to terms in where a and examples going We’re provided supporting treatment also and as appropriate states that that medications has of to the all what are they those for as for patients

state to So very continued be partnership important. is the at level going our

so been that VIVITROL settings we’re there, to we’ve we’ve continue care The is the in the in I’ve 'XX on growth continue to had of where drive As then past, expand outpatient. grow for going we’re successful to in in-patient through. in from expand and going success said pull to and goal some further of continued

and it’s the care support we’re of of of as state throughout to new across through settings through are that that to each looking are models necessary ensure collaborating of it’s well to that sure pull infrastructure rollout learning continued fully So the country. federal new those we funding the at the pull at commercial make that state we’re our models level, understood

Operator

you. Thank

Cowen. Our Shibutani next from go question of ahead. is Chris Please coming

Sandy Coombs

you there? are Chris,

Operator

not make sure on mute. Please phone is your

Chris Shibutani

on population? to of what was it bit range or guidance components up of year the sorry, XXXX? talked the of which in question Medicaid assumed bigger the acceleration. Can ranged would it I implies you’ve VIVITROL versus of What particularly that Is which to for of is in-patient terms slowing of little mute. a about talk question this but Can the maintained, X% The are you a mix growth it XX% little follow Is on this numbers? is patient and the From duration lower and I’m up bit kind components it that the are? picture, a for about range? in past? that be

Jim Robinson

it’s question. the Jim. Thanks for Chris,

next or growth guided range. that of all increase, year. an increase We X contain components little the X a a think I point to bit in

a see really this on expansion. business will we versus dynamic. more But We commercial of mix and state-by-state some that largest in continue continue do Medicaid to is toward growth that basis of patient at expansion our looking our really Medicaid – models in states

focused that midpoint XXXX. number terms look the help of you that length guidance, right of at of increased out therapy make So increased will therefore the of therapy it’s but if mainly the in growth. saw enhance around it’s in an reason, an duration obviously patients, we for that growth can And or the to of number ends a on we you’re if of us right And point used. again, inroads which is vials midpoint a

Chris Shibutani

terms more strikes then of treatment. seeing of that scenario a using penetration that the treatment, picture bigger broadly about in VIVITROL medication-assisted bit when me been it’s And growth we whether forms or think speaking that’s not why it we’re a always puzzle of other or

being point Thanks. about treatment having VIVITROL a view opioid that address that why addiction about of a really other portfolio you patients the access options specifically? perhaps Why your there expand talk addictions, Alkermes to have on to focus opposed wouldn’t strategy You Is able have embraces options? of as to all treatment forms. to commercially singularly the medication-assisted

Richard Pops

coming opioid a based federal backdrop conservative with states the downs increased the are Hi, think Chris. big we and system our ups It’s at the out some It’s progressively some is epidemic. and MAT Richard. we are all a against and described complex the you? and picture fragmented and estimate and states of you the that a the on exiting way I way with it. interesting It’s funding the our Jim good is into coming guidance question of where year moving really worsening market communications structure of in question How some core Jim in,

capacity things So when [indiscernible] for we to provide also over. for certain surge that have flip

we So, We states, rate future XXXX it. see in well. the Ohio non-linear a that Massachusetts alone. for potential happening just grew by example, at two by model we driven can’t and in And as

don’t more in of there’s it happens there’s MAT. question the So XXXX no whether use we for more and that XXXX, or know impetus but

within people year U.S. literally guidelines, the long-acting post the VIVITROL in undergo detoxification stamps comfortable indicated. so the naltrexone millions under not and of medically patients. most That X long-acting the people, becoming post that very MATs, on place naltrexone is without and There is detox are Now is that indicated. each initiation [ph] detox are in clear Alkermes or million detox

that’s It’s SUBOXONE not treatment patient for a different place So competing different objectives. a we’re who against where or methadone. has

features are some of the the to immediate of market and as So side have of these potential but long-acting the of for because will the But its we the as which address other community. market. perspective is they direction, what new in principle of fit that arising. because diversion to the I that addiction into We non-agonist treatments the plans we’re on unique your as always think final obviously interested it to well buprenorphine question part in well any is things don’t national we infrastructure our the in see liability we’re have part your buprenorphine new looking injectable of commercial of like the some move

Chris Shibutani

very Thanks Great. much.

Sandy Coombs

Donna. next Let’s take question the please,

Operator

you. Thank

Raffat ahead. of Evercore go Our Umer Please next question is from coming ISI.

Umer Raffat

Thanks certain color aggressive see a first, at just at is time. a had really could bit if or target Maybe guys. an certain you the And a do target. Perhaps I about top give capital at? we get mind have do whether number type Hi, think number trying have when for of I’ll I’m you Alkermes assets? trying what line deployment ultimate taking I side? the on sense something for couple profitability of Do these think questions. a EPS you in us as about Richard, number in you you’re get few. a a sort ups. one mind to my to had looking or – acquisitions M&A go line top I maybe on more of just could guess a I’m follow is you

Richard Pops

have two of advantage I’d development areas – acquisition been therapy complementary or the expertise. where capabilities hunting So and our we [ph] say major has R&D have areas historically been competitive

opportunity us by and The commercial adjacencies and hearing that’s building psychiatry you’re new platform with So component that anything necessity that been the say. has we’ve by to and It’s that historically and complex distinctive. VIVITROL you need a addiction market. now treatment service even of ARISTADA systems the enter and It’s calling and lot capabilities unique. to on order is in been providers additional where

for growth I’d metric pick first the than also top I looking we platform commercial is had time leverage by now with the financial high the rather platform. So to say a at that scientific And if we’re this motivated products. that were most quality moment at line adjacencies revenue

we’re that having the value-added its pedigree interested building the We differentiated for continue sake. own community medicines. in We’re might high very in bulk not of really

Umer Raffat

Got it.

and In commercial put of good. launch the I my that. was GAAP happened after is So million year on longwinded in then my was commercial performance already first Jim, guidance one XXX Jim so which XXXX. on million this it on of sort turning year SG&A ARISTADA in all of VIVITROL and up did The that for to have very question. XXXX, platform million an here’s XXX full perhaps R&D the XX%, one grew million. XXX from SG&A XX a GAAP up second

XXXX same guidance? strokes So therapeutic question explains what focus is I increase area the still per and the broad My of GAAP XX% versus as XXXX the SG&A XXXX. levels maybe just understand as is in

Jim Frates

start. I’ll afternoon. Umer, Good

VIVITROL I again, space before. key nature to sales that Jim a think gapping mentioned and about to the sure as key making we’re antipsychotic addicting, we we’ve the out capable the that Robinson grown market I have here show that the managers fully competitive we talked to schizophrenia is that a line, place, building competitive those think in managers And organization. account the in building continue sure out for reimbursement in and infrastructure long-term growth make looking both to in in that as field top have right also in match but in Rich

to investing with see So the ARISTADA these the I again market liner VIVITROL that show match in as we opportunity because we have yes, believe. accelerate long-term we opportunity SG&A absolutely that think going we’re and really the that in again have I have, been to growth growth but both

Umer Raffat

then last primary it. And just the a to little Got better. EVOLVE-MS-X’s was clarify maybe one endpoint

has cutoff qualify [ph] trial as on the makes a that the days with GI happen is, the criteria number on or a the So day what question is I guess either event. scale to certain not? it’s that really understanding the AE or comparing IGISIS day exactly my of the GI my

Richard Pops

knew get We’ll don’t. on I but the wish it I I answer Umer, to to you back that. it’s Rich.

Umer Raffat

No worries. very you Thank much.

Richard Pops

to I welcome. answered. more thing say want one that Jim the thing just You’re on

and we would and I as because have that incredible happening on Ohio the sorely in been because Massachusetts mistake. just commercial VIVITROL enjoyed were I sat and turned we would and We on it underpowered continuing if have And those had been I XXXX time. on relied think anomalies. side mentioned we disappointed were back growth in year-after-year, think a big

we’re states replicate able across to a the around addiction On ARISTADA, and the INVEGA more with a move So learned have side to XX-state for we we the most were just strategy. but space. getting another what SUSTENNA does to one be going. to take we And we is it’s on and most J&J up and ahead think competitive country marketplace we’re competitor the we against build what that of with products, competitive that what that’s and to try recent provide in we going it as market ARISTADA the

So of think ourselves that’s when question And ourselves we’re the I win? and now we just competing, positioning do you’re Jim We to think and instead we how what okay, like sizing is – around can we’re said, take to now. really now. feel compete particularly I that when our next win looked messaging hearing guided, we in Robinson

Operator

Thank you.

Please of from Our next go Stifel. ahead. question is Matteis coming Paul

Unidentified Analyst

Thanks. Nate to Paul. just question. Hi. for first on This going back is Maybe [ph] Umer’s

pursuit revenue that? out line then achieve any are how the kind of about of prioritizing to seeing growth, thinking you opportunities there? attractive you’re As top And you are

Richard Pops

whole you I’m going to give specificity here, a I of lot don’t think Nate.

addiction sit the obviously other terms squarely oncology those that I combinations sense. the pricing, really potential and think is that area aspect the a accounts I’d quite ones that and in that, interest interesting XXXX is Ones force could field capability, make lot aren’t because say of combinations IP XXXX number can the of of provide actually of emerging And differentiation. self-evident. adjacencies the immediately the concentric psychiatry, are you all are circles of and national of and But reimbursement there our prioritization predict. in

we’re actually looking at in now. So being what we’re pretty expansive

Unidentified Analyst

Great. Thanks.

Richard Pops

welcome. You’re

Operator

you. Thank

Jefferies. ahead. of go Our Amin next coming question is from Biren Please

Biren Amin

you there the Hi, Thanks and any with that you on Maybe takeaways are meeting? XXXX, had us FDA have with for my key that can share meeting pre-NDA from taking guys. questions.

Richard Pops

No.

have weeks in meeting later that year. few will meeting and in next We the request we the that expect to

Biren Amin

annualize XX% you it and reported of Okay. QX. to kind for And, on what guide growth when you ARISTADA, Richard, X% XXXX the QX suggests in

QX guess ARISTADA was question that it quarter-over-quarter, patients that Thanks. carry came XX% Do And another through? drove share other in given from I why So think shouldn’t growth grew switches you from ARISTADA that? in or therapies XXXX. new on

Jim Frates

it’s Jim. start. hi, I’ll Biren,

the year-end I first growth growth in the see that of historically think did and the in that first rate washes the course of reset it year we that the quarter, a seen think to through see bit We’ve each – little to in probably revenues plans trends overall decrease we’re inventory decreasing expect as I going quarter. we that mention system.

both make XX% quarter you perspective roughly or The that year-over-year Jim that if Robinson we typically from cyclicality fourth we’re a me, more to tends think looking seasonality fourth we see I just expected account in products. comment. perspective, at So into quarter be growth strong liner And quarter. of first see, rates not sense let excuse the the that our quite growth from and an growth take I’ll

Jim Robinson

patient growth cycle Obviously patients saw switching this injectable. both, we So medications, not surprising. It’s in patient as lot a of as from in another type will through well medications. long-acting starts new

generally So both. we it from see

Biren Amin

targeting greatest reps? sales reps to switches? would that with do are XX the have the that many patients on And you’ve ARISTADA with Is guess how I impact? be on where expanded prescribers going expect it then with, you those sales the And they or you force new new new

Jim Robinson

of hospital in our added current XX first team. to hospital going additional augment It’s the representatives we an to all, – be

in and all then us reach about we those perspective within an units were a have for of opportunity within on crisis breadth of is the depth stabilization a XX% that hospitals. the good So since hospitals. on coverage our There’s both the long-acting starts, starts really broaden make injectables happened to to hospitals

the that So we predominately see as new starts.

With new terms of of white reps, it was white space. a space filling XX in combination the

had of we geographies some that’s in cases opportunity that an in, starts. that higher so a frequency, particular the and historically then So be starts really mean for so as us our been it’s in had well. reach it’s as going resells of to new be not going to a to blend we where areas, be blend about new augmenting concentrated metropolitan could And well it’s as

Sandy Coombs

please. question next the take We’ll

Operator

Thank you.

Our coming Folkes from Please Cantor go Brandon next Fitzgerald. is question of ahead.

Brandon Folkes

some around sales the see later this you was strategy you. I how around could we be Thanks VIVITROL effort for that wondering questions. addiction could taking to additional VIVITROL? detox my color may year. And Thank incremental and Hi. give the this

Richard Pops

I’ll for opportunity us start XXXX. here. in question Without an that’s

one now question have That’s on on the for our available field minds. We a answer providers’ providers the resources team generally to to questions that how appropriately been have patient. detox number

So we patients patient. treating was was the with would provider how go in would with would a providing VIVITROL, about normally that or interested prospective sit the they I ask questions when detoxing

be have now So able typically the explain done. we how to to data that’s

to back we about it, support discussion goes about key of one us the And components that team. we do is we that. explain able being the to that’s the fully for So in that XXXX when had explain it’s field and office how reimbursement

of support much you of in patient what of is lack or So continuity a lack of population see care. this

a So how help it’s do you getting only not therapy stand them on but therapy. patient initiated

for opportunity a in that’s big XXXX. us So

Brandon Folkes

How dependence? much. Great. you within And do Thank VIVITROL’s just one you follow maybe up. alcohol view growth very

Jim Robinson

the That’s we’re whether market or use an it’s segment roughly whether XX% we’re fairly But ensure to of it’s our been disorder. that disorder to XX% That’s opportunities, I of all do stable. to use the evaluate think maximizing continuing every of opioid alcohol sales. overall

Brandon Folkes

much. you Thank Okay. very

Operator

Thank you.

Goodman SVB question Please go Our Marc of next is Leerink. coming from ahead.

Marc Goodman

Good morning. Two questions, first on XXXX.

of with peer more this us give study, patients, wondering switches? us thinking for Are then you’re for question be on learned running of thinking is that XXX that to here Is and us XXXX. anything you’re model? whole if numbers? an that how you in is we press you’ve be R&D about soon ZYPREXA a that that be us to there there year? guidance in with I strategy? you. shutdown, help you was naïve And the the can out the but this there we if Like forward and And you’ve spending you release Thank who product. program if can a the a on give to you’re an much this opportunity Can idea that scenarios with increase positioning an get has positioning how we be that respect just two the second this just the such decide that is how XXXX patients what lot year XXXX, take you could assuming would Now push you should going that of remind spending had this vice-versa, of that going discussions, sense of to much expenses you be would can been for

Richard Pops

I’ll So XXXX handle upfront.

have fully. We yet engage to payers

we’ll have engaging We this we’ll detailed side upcoming that just detailed have the build strategy summer do be boards to at ad information on point go-to-market year. payers within begun our have time more for the Once payers months. probably we the much this payers information, the and with in we’ll then and payers

of your at off and payer. a is benefit burden When look the overall my proposition but of though the terms So benefit that’s key quantifiable in the with you a benefit staying the If that establishing therapy mind pharmacoeconomic drop from a of in huge these also treating a a number of related answering medical value patients part of only of burden question, patients costs there’s XXXX to in of in patients. terms that illness XXXX XXXX. the illness of perspective, on benefit not of clinical that’s terms with

value do on clinical our as a we’ll more proposition look addition we’ll pharmacoeconomic to as that, a elements both is expectation proposition. profile to XXXX at well a modeling pharmacoeconomic the and the we have as more clinical perspective. value balanced of strong will proposition data value that us also other In release discuss But with well allow

switch in of your In it question of both. would be new terms patients, terms and other

Jim Robinson

about. million get whether on of scenarios that we guidance about, the agency, of more course for sort And the for – that the XXXX, talked at earmarked think I to would And the continue got advice study after the the course our obviously as stage. on XXXX. depending we’ve that talked through planning and this with the you and be know $XX the Rich we’ll it’s through year study of each we of Marc, But we’re range. meet approximately timing in in

Sandy Coombs

next take Donna, we’ll All right, please. question the thanks.

Operator

coming Our next question is from go Brill Danielle Piper Please of ahead. Jaffray.

Danielle Brill

Hi, questions. me. Two quick ones guys. morning. Thanks the from Good for

XXXX considering And if of you’re on and the presentation the data? can then is provide an you implications which First, medical I’m just meetings this VIVITROL for wondering update patent IPR potential invalidated?

Richard Pops

Danielle. Hi, It’s Rich.

We’re in April. in that’s looking then And the different Orlando. late there’s for in is One data. called And XXXX SIRS APA three May. in at meetings ASCP there’s May. That’s then the

think information can’t then and and we VIVITROL. extent market to they they a type to And scale try NDA or consistent the is we It If product, commercial this which with than in incumbent don’t, you patents But mix we to to by expected The So more requires prevail requires be say this November position last whoever that just protect compete. IPR and new should on in manufacturing before, be feel look should them Response IPR. you’ve expect Owner is come presentation. to manufacture large And somewhere We difficult more us a into there’s times that able submitted an clinical next that heard substitutable VIVITROL week I make many we take think at. our we VIVITROL the extremely then resolved XXXbX in submission our comes that to to very give at scale. strongly make. expanded me that that Patent upon about position IP I we’ll have the IPR. believe. it’s

our ability long-acting said, and create always off delivery technologies I’ve through come a as many So and – have naltrexone naltrexone that exist there’s people in product is patent. drug to the

Now it’s shown. the is difficult for done a of couple incredibly It’s we’ve and as hard reasons. market

competitive that’s as IP capacity think first and strong. as the the think build is and we we this government, we a federal important really this So this and presence for advantage in well. principle, states VIVITROL the commercial But policy communities and the capacity

win. We expect to

Sandy Coombs

please, Next question Donna.

Operator

of is Divan Vamil ahead. question Please Suisse. from next Credit Our coming go

Vamil Divan

Hi. Thanks for taking my questions.

some well. up just couple following as earlier So a on the questions of

diverse perspective, sort you’re you don’t wondering is of of it’s So spot XXXX, you second, pretty little year. of look too the of get thought now? for then one, think ourselves, just schizophrenia. a as terms out there I right 'XX. the say sweet And from a Obviously just to I’m you looking over in the positioned job a do XXXX, comments therapy? But in expenses have the was to and growth assumption was more we investment clinical I a at of maybe a would modeling discussion you around be market we’re guide XXXX patients more the bit frontline a following this the far ahead proper XXXX not maybe guys the is types side. in expenses appreciate that seeing that on lot 'XX factoring a than but more want just from in street where profile as our that patient your up models further, you of to is going best payer of kind there kind doing it see or a your as on discussions, think

sense Thanks. clinical see get just impact of and/or come from? impact So to pharmacoeconomic where you trying to I’m maybe a best the

Jim Frates

It’s Hi, Frates. Jim Vamil.

right on going we don’t There really the Just stick a VIVITROL practice with now with synergy side in ARISTADA 'XX of and going on is disparity we to typically XXXX of on expenses. the lot a to people the lot into nice varied revenues level it had don’t very we’re say obviously of that beyond very I on making include growth potential we’re we’re right-size and now. the people actually – health of feel people long-term key side and platform investment now and hospital of would model, managers certain models side and don’t and this for gives XXXX. obviously that guide a time the comfortable over that side, a the on us systems account lot

along synergies ARISTADA. XXXX you’ll in think I opportunity the with a in see with of schizophrenia lot So

it I’ll more closely to years. as those that we closer leave maybe we’ll and guide So to go

Jim Robinson

And I’ll a of been the just this look the add XXXX, how olanzapine at was in on ability historically control symptoms. for to rapidly segments you patient’s used, terms olanzapine if have appreciation

treatment patients issue effect widely from olanzapine. value suffering the why belief proposition that it – controlled over was of best rapid the the was schizophrenia. But was it was weight more were medicine key was were this for not treating used that gain side there time. of in this that Obviously, on the terms a it, So patients well then really the of those element

for see also XXXX controlled with be that would controlled I it for the with or long are So need gain not only now term over especially to XXXX. that attenuate weight we’re quickly weight patients able patients well but that

in I see patients candidly. used all being it So

obviously there’s given Now segmentation would long-acting a approach injectable. be who patients a we’ll taking from we also fact have the benefit

articulate very schizophrenia. in, segmentation to as terms would the where really and as from have be treating clearly draw would where the out. So a worked able clearly to picture in to fit patients of XXXX compelling We’ll well we’ll patient suffering patient in ARISTADA able as be segmentation and clear fit

Operator

Thank you.

Flynn next Please question Goldman of ahead. Our go coming is from Sachs. Terence

Holly Barra

the Terence. Hi. is Holly taking on for This for Thanks questions.

your your SG&A provide your additional details guidance. Thanks. another XXXX build Can on on for regarding Just one any you XXXX? assumptions

Jim Frates

Sure. commercial There almost for could inside last work. in no field guidance. At and of is what of we investment our there’s year. very this beginnings that point you – on XXXX, But to XXXX spending XXXX of it’s dollars marketing portion the actually feel similar were the a for education it in

VIVITROL in the in that to in organization started field be in XXXX we’re from the building growth using build of investment coming lot no that year. 'XX. next beyond mainly ARISTADA a what we annualized growth that for into organization for not that field we’re that – area. and obviously But And and there’s So is will QX

Sandy Coombs

time have more We for one question.

Operator

you. Thank

Akash Wolfe is ahead. coming today question Research. Tewari Please last of Our from go

Akash Tewari

Hi. taking my questions. Thanks for

be XXXX patients happen the real goes treatment of hear like seems they there In about also when initiation. it month discontinuations has So clinical about than also TECFIDERA in next-gen first how occur literature the in patent switching events disconnect we that onto talk the seems And GI happened expected, off to of you in in can most data. TECFIDERA a the what’s between earlier the and GI to do setting version? existing the what a opportunity the us event within world many

So as looking data, you type at? are head-to-head treatment at what your disconsolation of rate you look

Richard Pops

passed that, TEC. is is the this baton then commercial TEC of been in that’s quite remarkable world, commercial expertise. of Hi, the because where launch it most world approval people their safety basis below to Obviously, discontinuation Akash. entirely. large X%. I the NDA than discontinuation to would we the The in conduct It’s they’re you with study answer the Biogen summary what and see filed are the rate Rich. charge running that question the higher you, open important the real of label call and hear rate have trial And seeing we’re you agree real we’re information and clinical substantially from GI that in We

you world like Biogen patients weeks GI really think because to of the real we’re on to would differences, often early is the drug, that’s you the put we experienced launched. that is as the where first very, when in in differentiated going drug immediately I very and the separate for that are we So of specifics said, treatment, to when encourage their a But discomfort plan. have VUMERITY I feel go

Sandy Coombs

the everyone everybody, dialing Thanks QX that for right, in. call Alkermes All concludes for today.

If at company. don’t you to the have any hesitate follow-up out questions, please us reach to

Operator

your today’s for This participation. thank Ladies you gentlemen, concludes conference. and

your wonderful disconnect have and may day. time lines this You a at

Alkermes (ALKS) 14 Feb 192018 Q4 Earnings call transcript